Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6281

14 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6281). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)
Chemical structure diagram of Duloxetine hydrochloride, showing its key ring systems and functional groups in a two-dimensional format.*
FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)
A Kaplan-Meier curve graph comparing the proportion of patients with relapse over time (days) between placebo and Duloxetine treatments. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The graph shows a lower relapse proportion for Duloxetine compared to placebo.*
FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)
Kaplan-Meier estimator survival curve showing the proportion of patients with relapse over time from randomization to relapse (days). The chart compares two treatments, Placebo (dashed line) and Duloxetine (solid line), with Duloxetine showing a lower proportion of relapse over time.*
FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph shows multiple curves comparing pain improvement across these four groups.*
FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)
A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and placebo. The graph illustrates patient response distribution for pain improvement across these three groups.*
FDA Label Image

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)
A line chart comparing the percentage of patients reporting improvement at various levels of percent improvement in pain from baseline. It includes data for Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and placebo. The vertical axis shows the percentage of patients improved, while the horizontal axis depicts increasing percent improvement thresholds from >0 to 100.*
FDA Label Image

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)
A line graph showing the percentage of patients improved in relation to percent improvement in pain from baseline. Four groups are compared: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two different representations), and placebo. The y-axis represents the percentage of patients improved, and the x-axis shows percent improvement in pain from baseline.*
FDA Label Image

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)
A line chart showing the percentage of pediatric patients aged 13 to 17 years with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. It compares Duloxetine 60 mg once daily and placebo, plotting percent improvement in pain from baseline on the x-axis against the percentage of patients improved on the y-axis. Duloxetine shows consistently higher patient improvement percentages across pain improvement thresholds.*
FDA Label Image

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)
A line graph comparing the percentage of patients improved with Duloxetine 60/120 mg once daily versus placebo, plotted against percent improvement in pain from baseline (BOCF). The vertical axis shows percentage of patients improved, and the horizontal axis shows percent improvement in pain. Two curves represent placebo and Duloxetine treatment.*
FDA Label Image

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)
A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline, ranging from 0 to 100%, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Data points for both treatments are connected by lines, with Duloxetine consistently showing higher patient improvement percentages than placebo across the percent improvement range.*
FDA Label Image

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)
A line chart comparing the percentage of patients improved with placebo versus Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher improvement percentages than placebo across various pain improvement thresholds.*
FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)
Duloxetine 30 mg delayed-release capsules, shown in white and black capsules with a segmented design, containing multiple capsules arranged in a flower-like pattern. The capsules have an imprint visible but not readable in the image. The labeler is A-S Medication Solutions.*
FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)
Duloxetine 30 mg delayed-release capsules in a brown glass bottle with a black child-resistant cap. The label includes the product name Duloxetine, dosage form as delayed-release capsules, strength 30 mg, and the labeler A-S Medication Solutions. The bottle container is visible along with the label printed in dark colors on a white background.*
FDA Label Image

Label Image (Lbl500906281)

Label Image (Lbl500906281)
Label for Duloxetine 30 mg delayed-release capsules by A-S Medication Solutions. The label displays the NDC 50090-6281-0 and indicates the package contains 30 capsules. It includes storage instructions to store at 77 degrees Fahrenheit and dosage packaging information with a unique package insert number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.